August 4, 2016
Verily, formerly Google Life Sciences, teams up with GlaxoSmithKline to develop bioelectronic medicines that can “harness electrical signals in the body to treat chronic disease.” Both companies […]
August 11, 2016
Strimvelis is the first gene-therapy cure for a rare disorder. Its recently announced cost of $665,000 makes it one of the most expensive one-time treatments ever sold. However, […]
August 18, 2016
When measuring success in pharma, one highly monitored measurement is the amount of revenue a company generates from new medicines. But is it a reliable measure […]
August 19, 2016
Electronics developer and interconnected solutions company Molex is buying Phillips-Medisize for an undisclosed amount, with an expected closing date in the fall. Molex and Phillips-Medisize’s combined skills will help […]
August 19, 2016
The ongoing patent battle over who owns the rights to the CRISPR-Cas9 technology has heated up with a new email. Biochemist Dr. Jennifer Doudna, from the University of […]
August 19, 2016
Merck & Co. Inc. has shown interest in buying Medivation Inc. earlier this month. Medivation, best known for its prostate cancer drug Xtandi, has already rejected […]
August 19, 2016
Featuring CEO Interview with Gur Roshwalb, MD, CEO, Akari Therapeutics Plc Volume 3, Number 6 Whether you are or you require executive or management talent […]
September 9, 2016
Allergan CEO Brent Saunders promised in his CEO blog Tuesday to limit price increases, becoming the first CEO of a major drugmaker to do so. Prices […]
September 22, 2016
Emma Walmsley was chosen to be the next Chief Executive Officer of GlaxoSmithKline this week, making her the first woman to lead a top-25 drugmaker. She […]